Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1 9Phase 1/2 6Phase 3 5Phase NA 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

EGFR Positive Non-small Cell Lung Cancer 1

Interventions

Radiosurgery 6pembrolizumab 5Oncolytic Virotherapy 4Magnetic Resonance Spectroscopy 4Fluorodeoxyglucose F18 4Carboplatin 4Paclitaxel 3Cyclophosphamide 3Cisplatin 3osimertinib 2atezolizumab 2aldesleukin 2Tobacco Use Cessation Devices 2Specimen Handling 2Radiotherapy 2Positron-Emission Tomography 2Pemetrexed 2Nivolumab 2Docetaxel 2toripalimab 1sugemalimab 1sodium thiosulfate 1perflutren 1palbociclib 1icotinib 1gallium 68 PSMA-11 1fludarabine 1durvalumab 1dapagliflozin 1dacomitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × toripalimab × Thoracic × Clear all
NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Fujian Cancer Hospital

Phase EARLY_PHASE1 Unknown
40 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡